pantoprazole has been researched along with Gastroduodenal Ulcer in 86 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy of adjunctive therapy with curcumin on the eradication of Helicobacter pylori infection and severity of dyspepsia in patients with PU." | 9.22 | Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. ( Biglarian, O; Ghamarchehreh, ME; Khonche, A; Majeed, M; Panahi, Y; Sahebkar, A; Soflaei, SS; Valizadegan, G, 2016) |
| "In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 9.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 9.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 9.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 9.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "After endoscopic treatment of bleeding peptic ulcers, intravenous pantoprazole is more effective than ranitidine for the prevention of rebleeding." | 6.78 | Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding. ( Demetrashvili, ZM; Ekaladze, EN; Kamkamidze, GK; Lashkhi, IM, 2013) |
| "To determine the plasma concentration of pantoprazole sodium by high performance liquid chromatography and its distribution in patients with different CYP2C19 genotypes in an attempt to provide experimental data for the clinical dosage adjustment of the drug." | 5.35 | Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism. ( Jiang, W; Li, KQ; Lu, JR; Shao, JG; Sun, YY, 2009) |
| "To assess the efficacy of adjunctive therapy with curcumin on the eradication of Helicobacter pylori infection and severity of dyspepsia in patients with PU." | 5.22 | Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. ( Biglarian, O; Ghamarchehreh, ME; Khonche, A; Majeed, M; Panahi, Y; Sahebkar, A; Soflaei, SS; Valizadegan, G, 2016) |
| "In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions." | 5.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 5.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "We followed up 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1), and compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls." | 5.11 | The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 5.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 5.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Pantoprazole is a proton pump inhibitor that is commonly used in the treatment of peptic ulcer disease (PUD) and metabolized by cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4." | 3.85 | Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ( Altinbas, A; Babaoglu, MO; Bozkurt, A; Goktas, MT; Kalkisim, S; Karaca, RO; Kilincalp, S; Yasar, U; Yuksel, I, 2017) |
| "Following healing of endoscopically confirmed peptic ulcer or reflux oesophagitis during 4-12 weeks' treatment with pantoprazole (40-80 mg/day), adult patients received open-label maintenance treatment with pantoprazole (40-160 mg/day) for up to 15 years in a single centre combined study (10-year initial study; 5-year extension study)." | 3.78 | Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. ( Athmann, C; Brunner, G; Schneider, A, 2012) |
| "The aim of this study is to assess the prevalence of peptic ulcer rebleeding by comparing patients who received omeprazole versus pantoprazole i." | 3.76 | [Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors]. ( de Sousa, M; Garrido, A; Iborra, MI; Saperas, E, 2010) |
| " pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole." | 3.76 | Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. ( Bielicki, D; Droździk, M; Gawrońska-Szklarz, B; Kurzawski, M; Marlicz, W; Siuda, A, 2010) |
| "Stress ulcer prophylaxis (SUP) using ranitidine, a histamine H2 receptor antagonist, has been associated with an increased risk of ventilator-associated pneumonia." | 3.75 | Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. ( Bowton, DL; Houle, TT; Kincaid, EH; MacGregor, DA; Miano, TA; Reichert, MG, 2009) |
| "This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years." | 3.73 | Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. ( Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005) |
| " pylori eradication in peptic ulcer patients treated with pantoprazole." | 3.73 | Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. ( Droździk, M; Gawrońska-Szklarz, B; Kurzawski, M; Siuda, A; Starzyńska, T; Wrześniewska, J, 2006) |
| "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses." | 3.71 | Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases. ( Athmann, C; Boldt, JH; Brunner, G, 2001) |
| "After endoscopic treatment of bleeding peptic ulcers, intravenous pantoprazole is more effective than ranitidine for the prevention of rebleeding." | 2.78 | Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding. ( Demetrashvili, ZM; Ekaladze, EN; Kamkamidze, GK; Lashkhi, IM, 2013) |
| " We performed serial endoscopy, checked for adverse events, and laboratory values." | 2.70 | Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001) |
| "Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments." | 2.45 | Pantoprazole: a proton pump inhibitor. ( Moreira Dias, L, 2009) |
| "Pantoprazole has been assessed in most of the clinical situations where acid suppression is required, and showed great efficacy and an excellent safety profile." | 2.44 | Pantoprazole: from drug metabolism to clinical relevance. ( Bardou, M; Martin, J, 2008) |
| "Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion." | 2.42 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003) |
| " While the short-term risk of complications appears to be minimal, the tolerance of these drugs in chronic use requires careful monitoring because of the potential consequences of prolonged inhibition of acid secretion." | 2.40 | [Proton pump inhibitors in pediatrics]. ( Faure, C; Languepin, J; Pelatan, C, 1999) |
| "Pantoprazole is a proton pump inhibitor which has recently had its clinical license extended to include maintenance therapy for the treatment of reflux oesophagitis, Helicobacter pylori eradication and short-term intravenous administration." | 2.40 | Pantoprazole, Prout and the proton pump. ( Modlin, I; Playford, RJ; Podas, T, 1999) |
| " Minor adverse events include headache, diarrhoea, dizziness, pruritus and rash." | 2.39 | Safety of proton pump inhibitors--an overview. ( Arnold, R, 1994) |
| " Pantoprazole formulated in an enteric-coated tablet displays high bioavailability and linear pharmacokinetics whether on single or multiple dose regimens." | 2.39 | Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. ( Huber, R; Kohl, B; Sachs, G; Senn-Bilfinger, J; Simon, WA; Sturm, E, 1995) |
| " It has a high and constant bioavailability (approximately 77%) which does not change on multiple dosing, so that maximum blood levels are achieved after the first dose." | 2.39 | Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. ( Parsons, ME, 1996) |
| "Combination therapy for GERD is preferred in patients with EE." | 1.72 | [Esophagoprotective therapy in patients with erosive esophagitis]. ( Bakulina, NV; Ilchishina, TA; Tikhonov, SV; Topalova, YG; Vasiliev, RV, 2022) |
| "Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
| "To determine the plasma concentration of pantoprazole sodium by high performance liquid chromatography and its distribution in patients with different CYP2C19 genotypes in an attempt to provide experimental data for the clinical dosage adjustment of the drug." | 1.35 | Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism. ( Jiang, W; Li, KQ; Lu, JR; Shao, JG; Sun, YY, 2009) |
| "Proton pump inhibitors play an important role in increasing the bioavailability of antibiotics in the gastric mucus by altering gastric volumes and increasing the stability of some antibiotics, e." | 1.33 | Helicobacter pylori: factors affecting eradication and recurrence. ( Vakil, N, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (25.58) | 18.2507 |
| 2000's | 34 (39.53) | 29.6817 |
| 2010's | 23 (26.74) | 24.3611 |
| 2020's | 7 (8.14) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Halling, CMB | 1 |
| Møller, MH | 8 |
| Marker, S | 7 |
| Krag, M | 8 |
| Kjellberg, J | 1 |
| Perner, A | 7 |
| Gyrd-Hansen, D | 1 |
| Vaezi, MF | 1 |
| Brunton, S | 1 |
| Mark Fendrick, A | 1 |
| Howden, CW | 1 |
| Atkinson, C | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Spechler, SJ | 1 |
| Bakulina, NV | 1 |
| Tikhonov, SV | 1 |
| Topalova, YG | 1 |
| Ilchishina, TA | 1 |
| Vasiliev, RV | 1 |
| Schefold, JC | 4 |
| Wetterslev, J | 5 |
| Wise, MP | 4 |
| Borthwick, M | 4 |
| Bendel, S | 4 |
| Keus, F | 4 |
| Guttormsen, AB | 4 |
| Lange, T | 5 |
| Granholm, A | 4 |
| Zampieri, FG | 1 |
| Thorsen-Meyer, HC | 1 |
| Kaas-Hansen, BS | 1 |
| van der Horst, ICC | 2 |
| Horvath, A | 1 |
| Leber, B | 1 |
| Feldbacher, N | 1 |
| Steinwender, M | 1 |
| Komarova, I | 1 |
| Rainer, F | 1 |
| Blesl, A | 1 |
| Stadlbauer, V | 1 |
| Harhay, MO | 1 |
| Young, PJ | 1 |
| Shankar-Hari, M | 1 |
| Alhazzani, W | 1 |
| Pelosi, P | 1 |
| Meyhoff, TS | 2 |
| El-Kersh, K | 1 |
| Jalil, B | 1 |
| McClave, SA | 1 |
| Cavallazzi, R | 1 |
| Guardiola, J | 1 |
| Guilkey, K | 1 |
| Persaud, AK | 1 |
| Furmanek, SP | 1 |
| Guinn, BE | 1 |
| Wiemken, TL | 1 |
| Alhariri, BC | 1 |
| Kellie, SP | 1 |
| Saad, M | 1 |
| Rasmussen, BS | 2 |
| Siegemund, M | 1 |
| Bundgaard, H | 1 |
| Elkmann, T | 2 |
| Jensen, JV | 1 |
| Nielsen, RD | 1 |
| Liboriussen, L | 1 |
| Bestle, MH | 1 |
| Elkjær, JM | 1 |
| Palmqvist, DF | 1 |
| Bäcklund, M | 1 |
| Laake, JH | 2 |
| Bådstøløkken, PM | 1 |
| Grönlund, J | 1 |
| Breum, O | 1 |
| Walli, A | 1 |
| Winding, R | 1 |
| Iversen, S | 1 |
| Jarnvig, IL | 1 |
| White, JO | 1 |
| Brand, B | 1 |
| Madsen, MB | 1 |
| Quist, L | 1 |
| Thornberg, KJ | 1 |
| Møller, A | 1 |
| Wiis, J | 1 |
| Anthon, CT | 1 |
| Hjortrup, PB | 1 |
| Aagaard, SR | 1 |
| Andreasen, JB | 1 |
| Sørensen, CA | 1 |
| Haure, P | 1 |
| Hauge, J | 1 |
| Hollinger, A | 1 |
| Scheuzger, J | 1 |
| Tuchscherer, D | 1 |
| Vuilliomenet, T | 1 |
| Takala, J | 1 |
| Jakob, SM | 1 |
| Vang, ML | 1 |
| Pælestik, KB | 1 |
| Andersen, KLD | 1 |
| Dieperink, W | 1 |
| Fjølner, J | 1 |
| Kjer, CKW | 1 |
| Sølling, C | 1 |
| Sølling, CG | 1 |
| Karttunen, J | 1 |
| Morgan, MPG | 1 |
| Sjøbø, B | 1 |
| Engstrøm, J | 1 |
| Agerholm-Larsen, B | 1 |
| Moayyedi, P | 1 |
| Eikelboom, JW | 1 |
| Bosch, J | 1 |
| Connolly, SJ | 1 |
| Dyal, L | 1 |
| Shestakovska, O | 1 |
| Leong, D | 1 |
| Anand, SS | 1 |
| Störk, S | 1 |
| Branch, KRH | 1 |
| Bhatt, DL | 1 |
| Verhamme, PB | 1 |
| O'Donnell, M | 1 |
| Maggioni, AP | 1 |
| Lonn, EM | 1 |
| Piegas, LS | 1 |
| Ertl, G | 1 |
| Keltai, M | 1 |
| Cook Bruns, N | 1 |
| Muehlhofer, E | 1 |
| Dagenais, GR | 1 |
| Kim, JH | 1 |
| Hori, M | 1 |
| Steg, PG | 1 |
| Hart, RG | 1 |
| Diaz, R | 1 |
| Alings, M | 1 |
| Widimsky, P | 1 |
| Avezum, A | 1 |
| Probstfield, J | 1 |
| Zhu, J | 1 |
| Liang, Y | 1 |
| Lopez-Jaramillo, P | 1 |
| Kakkar, A | 1 |
| Parkhomenko, AN | 1 |
| Ryden, L | 1 |
| Pogosova, N | 1 |
| Dans, A | 1 |
| Lanas, F | 1 |
| Commerford, PJ | 1 |
| Torp-Pedersen, C | 1 |
| Guzik, T | 1 |
| Vinereanu, D | 1 |
| Tonkin, AM | 1 |
| Lewis, BS | 1 |
| Felix, C | 1 |
| Yusoff, K | 1 |
| Metsarinne, K | 1 |
| Fox, KAA | 1 |
| Yusuf, S | 1 |
| Bestle, M | 1 |
| Arenkiel, B | 1 |
| Kamper, MK | 1 |
| Lång, M | 1 |
| Pawlowicz-Dworzanska, MB | 1 |
| Karlsson, S | 1 |
| Liisanantti, J | 1 |
| Dey, N | 1 |
| Knudsen, H | 1 |
| Demetrashvili, ZM | 1 |
| Lashkhi, IM | 1 |
| Ekaladze, EN | 1 |
| Kamkamidze, GK | 1 |
| Metanat, HA | 1 |
| Valizadeh, SM | 1 |
| Fakheri, H | 2 |
| Maleki, I | 2 |
| Taghvaei, T | 2 |
| Hosseini, V | 2 |
| Bari, Z | 1 |
| Kruszelnicka, O | 1 |
| Świerszcz, J | 1 |
| Bednarek, J | 1 |
| Chyrchel, B | 1 |
| Surdacki, A | 1 |
| Nessler, J | 1 |
| Khonche, A | 1 |
| Biglarian, O | 1 |
| Panahi, Y | 1 |
| Valizadegan, G | 1 |
| Soflaei, SS | 1 |
| Ghamarchehreh, ME | 1 |
| Majeed, M | 1 |
| Sahebkar, A | 1 |
| Karaca, RO | 1 |
| Kalkisim, S | 1 |
| Altinbas, A | 1 |
| Kilincalp, S | 1 |
| Yuksel, I | 1 |
| Goktas, MT | 1 |
| Yasar, U | 1 |
| Bozkurt, A | 1 |
| Babaoglu, MO | 1 |
| Hong, EJ | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Shon, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Shao, JG | 1 |
| Jiang, W | 1 |
| Li, KQ | 1 |
| Lu, JR | 1 |
| Sun, YY | 1 |
| Miano, TA | 1 |
| Reichert, MG | 1 |
| Houle, TT | 1 |
| MacGregor, DA | 1 |
| Kincaid, EH | 1 |
| Bowton, DL | 1 |
| Choi, KD | 1 |
| Kim, N | 2 |
| Jang, IJ | 1 |
| Park, YS | 2 |
| Cho, JY | 1 |
| Kim, JR | 1 |
| Shin, JM | 1 |
| Jung, HC | 2 |
| Song, IS | 2 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Lam, KF | 1 |
| Chu, WM | 1 |
| Chan, P | 1 |
| Ling, YH | 1 |
| Kng, C | 1 |
| Yuen, WC | 1 |
| Lau, YK | 1 |
| Kwan, A | 1 |
| Wong, BC | 1 |
| Moreira Dias, L | 1 |
| Sung, JJ | 1 |
| Lau, JY | 1 |
| Ching, JY | 1 |
| Wu, JC | 1 |
| Lee, YT | 1 |
| Chiu, PW | 1 |
| Leung, VK | 1 |
| Wong, VW | 1 |
| Chan, FK | 1 |
| Garrido, A | 1 |
| Iborra, MI | 1 |
| Saperas, E | 1 |
| de Sousa, M | 1 |
| Craig, DG | 1 |
| Thimappa, R | 1 |
| Anand, V | 1 |
| Sebastian, S | 1 |
| Gawrońska-Szklarz, B | 2 |
| Siuda, A | 2 |
| Kurzawski, M | 2 |
| Bielicki, D | 1 |
| Marlicz, W | 1 |
| Droździk, M | 2 |
| Kim, JY | 1 |
| Park, HK | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Lee, SH | 1 |
| Hwang, JH | 1 |
| Kim, JW | 1 |
| Jeong, SH | 1 |
| Lee, DH | 1 |
| Nam, RH | 1 |
| Kim, JM | 1 |
| Lee, JH | 1 |
| Miranda, WR | 1 |
| Smith, JM | 1 |
| Burton, MC | 1 |
| Shcherbakov, PL | 1 |
| Ianova, OB | 1 |
| Belousova, NL | 1 |
| Masharova, AA | 1 |
| Shcherbakova, MIu | 1 |
| Goncharenko, LS | 1 |
| Firsova, LD | 1 |
| Kim, VA | 1 |
| Govorun, VM | 1 |
| Kashnikov, VS | 1 |
| Brunner, G | 3 |
| Athmann, C | 2 |
| Schneider, A | 2 |
| Sardarian, H | 1 |
| Mokhtare, M | 1 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Boixeda, D | 2 |
| Bermejo, F | 2 |
| Martín-De-Argila, C | 1 |
| López-Sanromán, A | 1 |
| Defarges, V | 1 |
| Hernández-Ranz, F | 1 |
| Milicua, JM | 1 |
| García-Plaza, A | 1 |
| Cheer, SM | 1 |
| Prakash, A | 1 |
| Faulds, D | 1 |
| Lamb, HM | 1 |
| Leitner, A | 1 |
| Zöllner, P | 1 |
| van Hout, BA | 1 |
| Klok, RM | 1 |
| Brouwers, JR | 1 |
| Postma, MJ | 1 |
| Martín De Argila, C | 1 |
| López Sanromán, A | 1 |
| Hernández Ranz, F | 1 |
| García Plaza, A | 1 |
| Luo, JY | 1 |
| Niu, CY | 1 |
| Wang, XQ | 1 |
| Zhu, YL | 1 |
| Gong, J | 1 |
| Bochenek, WJ | 1 |
| Peters, S | 1 |
| Fraga, PD | 1 |
| Wang, W | 1 |
| Mack, ME | 1 |
| Osato, MS | 1 |
| El-Zimaity, HM | 1 |
| Davis, KD | 1 |
| Graham, DY | 1 |
| van Rensburg, CJ | 1 |
| Hartmann, M | 1 |
| Thorpe, A | 1 |
| Venter, L | 1 |
| Theron, I | 1 |
| Lühmann, R | 2 |
| Wurst, W | 1 |
| Maltz, C | 1 |
| Bustamante Baléna, M | 1 |
| Ponce García, J | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Longoa, MG | 1 |
| Scarcelli, C | 1 |
| Orsitto, G | 1 |
| Perri, FC | 1 |
| D'Ambrosio, LP | 1 |
| Leandro, G | 1 |
| Diav-Citrin, O | 1 |
| Arnon, J | 1 |
| Shechtman, S | 1 |
| Schaefer, C | 1 |
| van Tonningen, MR | 1 |
| Clementi, M | 1 |
| De Santis, M | 1 |
| Robert-Gnansia, E | 1 |
| Valti, E | 1 |
| Malm, H | 1 |
| Ornoy, A | 1 |
| Bardhan, KD | 3 |
| Bishop, AE | 2 |
| Polak, JM | 2 |
| Romanska, HM | 1 |
| Rowland, A | 2 |
| Thompson, M | 2 |
| Morris, P | 2 |
| Schaefer-Preuss, S | 1 |
| Luehmann, R | 1 |
| McCaldin, B | 2 |
| Singh, G | 1 |
| Triadafilopoulos, G | 1 |
| Hsu, PI | 1 |
| Lai, KH | 1 |
| Lin, CK | 1 |
| Chen, WC | 1 |
| Yu, HC | 1 |
| Cheng, JS | 1 |
| Tsay, FW | 1 |
| Wu, CJ | 1 |
| Lo, CC | 1 |
| Tseng, HH | 1 |
| Yamaoka, Y | 1 |
| Chen, JL | 1 |
| Lo, GH | 1 |
| Vakil, N | 1 |
| Calvet, X | 1 |
| Gomollón, F | 1 |
| Armstrong, D | 1 |
| Manes, G | 1 |
| Ferrara, EC | 1 |
| Porro, GB | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Sezgin, O | 1 |
| Altintaş, E | 1 |
| Uçbilek, E | 1 |
| Tombak, A | 1 |
| Tellioğlu, B | 1 |
| Al-Sabah, S | 1 |
| Barkun, AN | 1 |
| Herba, K | 1 |
| Adam, V | 1 |
| Fallone, C | 1 |
| Mayrand, S | 1 |
| Pomier-Layrargues, G | 1 |
| Kennedy, W | 1 |
| Bardou, M | 2 |
| Martin, J | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Creutzfeldt, W | 2 |
| Harke, U | 1 |
| Arnold, R | 1 |
| Huber, R | 1 |
| Kohl, B | 1 |
| Sachs, G | 1 |
| Senn-Bilfinger, J | 1 |
| Simon, WA | 1 |
| Sturm, E | 1 |
| Wilson, BV | 1 |
| Knudsen, T | 1 |
| Lamers, CB | 1 |
| Parsons, ME | 1 |
| Meyer, UA | 1 |
| Leonhardt, U | 1 |
| Ritzel, U | 1 |
| Ramadori, G | 1 |
| Bateman, DN | 1 |
| Adamek, RJ | 2 |
| Szymanski, C | 2 |
| Pfaffenbach, B | 2 |
| Seelis, RE | 1 |
| Dohmen, W | 1 |
| Müller, P | 1 |
| Simon, B | 1 |
| Treiber, G | 1 |
| Lambert, JR | 1 |
| Faure, C | 1 |
| Pelatan, C | 1 |
| Languepin, J | 1 |
| Ellenrieder, V | 1 |
| Boeck, W | 1 |
| Richter, C | 1 |
| Marre, R | 1 |
| Adler, G | 1 |
| Glasbrenner, B | 1 |
| Playford, RJ | 1 |
| Podas, T | 1 |
| Modlin, I | 1 |
| Giannini, E | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Chiarbonello, B | 1 |
| Malfatti, F | 1 |
| Botta, F | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Savarino, V | 1 |
| Testa, R | 1 |
| Boldt, JH | 1 |
| Cherian, P | 1 |
| Romanska, H | 1 |
| Perry, MJ | 1 |
| Fischer, R | 1 |
| Ng, W | 1 |
| Barth, J | 1 |
| Hahne, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)[NCT02467621] | Phase 4 | 3,350 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy[NCT02718261] | Phase 4 | 3,350 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [NCT00153725] | 156 participants | Interventional | 2003-02-28 | Completed | |||
| Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes[NCT02345239] | Phase 3 | 14 participants (Anticipated) | Interventional | 2015-02-28 | Not yet recruiting | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Data for landmark mortality 1 year after randomization. (NCT02467621)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 610 |
| Normal Saline | 601 |
Landmark mortality 90-days after randomization (NCT02467621)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 510 |
| Normal Saline | 499 |
Number of participants with one or more episodes of clinically important GI bleeding in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 41 |
| Normal Saline | 69 |
Composite outcome of the number of participants with one or more of the mentioned conditions in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 360 |
| Normal Saline | 372 |
Number of participants with one or more episodes of pneumonia or clostridium difficile infection in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 276 |
| Normal Saline | 279 |
Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema. (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 0 |
| Normal Saline | 0 |
Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy (NCT02467621)
Timeframe: Within 90 days
| Intervention | percentage of days (Number) |
|---|---|
| Proton Pump Inhibitor (PPI) | 92 |
| Normal Saline | 92 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
20 reviews available for pantoprazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Pantoprazole: a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; E | 2003 |
[Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2005 |
Intravenous proton pump inhibitor therapy: a rationale for use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
Pantoprazole: from drug metabolism to clinical relevance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Gastroesophage | 2008 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
[Are proton pump inhibitors safe?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Carcinogenicity | 1994 |
Safety of proton pump inhibitors--an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cytochrome P-450 Enzyme System; Di | 1994 |
Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enzyme Inhibitors; Humans; | 1995 |
The changing role of H2-receptor antagonists in acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1996 |
Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimid | 1996 |
Triple therapy as a cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimi | 1996 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
[Proton pump inhibitors in pediatrics].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Child; Enzyme Inh | 1999 |
Pantoprazole, Prout and the proton pump.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Femal | 1999 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
30 trials available for pantoprazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
The effects of pantoprazole vs. placebo on 1-year outcomes, resource use and employment status in ICU patients at risk for gastrointestinal bleeding: a secondary analysis of the SUP-ICU trial.
Topics: Employment; Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Peptic Ulcer; P | 2022 |
Outcomes of Prophylactic Pantoprazole in Adult Intensive Care Unit Patients Receiving Dialysis: Results of a Randomized Trial.
Topics: Acute Kidney Injury; Aged; Clostridium Infections; Critical Care; Cross Infection; Female; Gastroint | 2019 |
Predictors of gastrointestinal bleeding in adult ICU patients in the SUP-ICU trial.
Topics: Adult; Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Peptic Ulcer; Simpli | 2021 |
Stress ulcer prophylaxis in the intensive care unit trial: detailed statistical analysis plan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Care; Critical Illness; Data Interpretation, Stati | 2017 |
Enteral nutrition as stress ulcer prophylaxis in critically ill patients: A randomized controlled exploratory study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Aged; Anti-Ulcer Agents; Critical Illness; D | 2018 |
Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.
Topics: Aged; Critical Illness; Female; Gastrointestinal Hemorrhage; Humans; Injections, Intravenous; Intens | 2018 |
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Dose-Response Relation | 2019 |
Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial.
Topics: Aged; Anti-Ulcer Agents; Critical Care; Double-Blind Method; Female; Follow-Up Studies; Gastrointest | 2019 |
Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Adult; Aged; Female; Hemorrhag | 2013 |
Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2015 |
Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2016 |
Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2009 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
[Enterofuril eradication therapy in chronic inflammatory diseases of the upper digestive tract].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Chronic Disease; Clarithromyc | 2011 |
Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2013 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alkalies; Anti-Ulcer Agents; B | 2003 |
Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben | 2004 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benz | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2005 |
Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2007 |
Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enterochromaffin Cells; Eso | 1994 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
[The action of the proton pump inhibitor pantoprazol against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled, double blind comparison].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Benzimidazoles; Cyclooxy | 1998 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2001 |
36 other studies available for pantoprazole and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
[Esophagoprotective therapy in patients with erosive esophagitis].
Topics: Antacids; Chondroitin Sulfates; Esophagitis; Gastroesophageal Reflux; Humans; Hyaluronic Acid; Panto | 2022 |
Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial.
Topics: Adult; Bayes Theorem; Humans; Intensive Care Units; Pantoprazole; Peptic Ulcer; Simplified Acute Phy | 2020 |
The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study.
Topics: Aged; Alkaline Phosphatase; Anti-Ulcer Agents; Aspartate Aminotransferases; Bacillus; Clostridiales; | 2020 |
Could stress ulcer prophylaxis increase mortality in high-acuity patients?
Topics: Adult; Histamine H2 Antagonists; Humans; Intensive Care Units; Pantoprazole; Peptic Ulcer; Ulcer | 2020 |
Stress Ulcer Prophylaxis-Friend or Foe?
Topics: Critical Illness; Humans; Pantoprazole; Peptic Ulcer; Pilot Projects; Ulcer | 2017 |
Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Arginine; Coronary Artery Disease; Cross-Sectional St | 2016 |
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; ATP Binding Cassette Transport | 2017 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cytoch | 2009 |
Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Distribution; Aged; Anti-Ulcer Agents; Area Unde | 2009 |
Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
[Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Costs; Female; Health Resources; Hospital Costs; | 2010 |
Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Gastrointestinal Hemorrhage; Hospitals, Teach | 2010 |
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
33-year-old woman with epigastric pain and hematemesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Diagnosis, Differential; Eosinoph | 2012 |
Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Esophagitis, Peptic; Female; Gastric Mucosa; Helicob | 2012 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
[Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Stability; Drug Sto | 2002 |
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
Dosage of intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastrointestinal Hemorrh | 2003 |
Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cell Count; | 2005 |
Helicobacter pylori: factors affecting eradication and recurrence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Eradication of Helicobacter pylori and dosages of esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti- | 2006 |
Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alleles; Amoxicillin; Anti- | 2006 |
Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Canada; Cost-Benefit Analysis; Decision Trees; Dose-Respons | 2008 |
Management of Acid-Related Diseases: Focus on Pantoprazole. Proceedings of the 1st International Symposium on Pantoprazole. Berlin, Germany, 1 May 1993.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastroe | 1994 |
[Pantoprazole. A new acid pump inhibitor against peptic ulcer and reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Hum | 1996 |
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 1996 |
[Do other proton pump blockers have advantages over Antra (omeprazole)?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Om | 1996 |
[2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Om | 1996 |
Proton-pump inhibitors: three of a kind?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Human | 1997 |
[Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Female; He | 1998 |
Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Edema; Female; Hu | 2001 |